Physician profile
Samuel K Box
NPI 1396973863
$3,392.68
in general payments reported to CMS, 2019-2025
30 companies · $44.22 in 2025
The $44.22 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.73 · 2020: $27.74 · 2021: $1,291 · 2022: $1,422 · 2023: $499 · 2024: $41.96 · 2025: $44.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $584.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.77 | 2021-2023 | Vraylar, Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $392.38 | 2021-2023 | Trintellix |
| Novo Nordisk INC | $347.16 | 2021-2023 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $229.96 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.76 | 2021-2023 | Jardiance |
| Tris Pharma INC | $222.36 | 2022-2023 | Dyanavel Xr |
| Amgen INC. | $196.35 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $172.66 | 2022 | |
| Corium, LLC | $148.48 | 2022-2023 | Azstarys |
| Pfizer INC. | $135.43 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $129.35 | 2022-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Lilly USA, LLC | $95.06 | 2021-2023 | Trulicity, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $81.05 | 2022-2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $74.68 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $65.59 | 2019-2025 | Austedo Xr |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $64.86 | 2021 | |
| Harmony Biosciences LLC | $33.32 | 2024-2025 | |
| Shield Therapeutics INC | $32.97 | 2023 | Accrufer |
| Bausch Health US, LLC | $27.67 | 2022 | |
| Braeburn INC. | $27.41 | 2024 | Brixadi |
| Janssen Pharmaceuticals, INC | $27.01 | 2021-2023 | Xarelto |
| Astellas Pharma US INC | $25.20 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.65 | 2023 | |
| Abbott Laboratories | $16.15 | 2022 | |
| Amarin Pharma, INC. | $15.47 | 2021 | |
| Ibsa Pharma INC. | $15.08 | 2022 | |
| Genentech USA, INC. | $13.94 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.21 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.13 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Box listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.